Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Favipiravir

Favipiravir: A Comprehensive Overview of the Antiviral Agent

Introduction

Favipiravir, a broad-spectrum antiviral agent, gained widespread attention during the COVID-19 pandemic due to its potential efficacy in treating viral infections. Originally developed in Japan under the name T-705 by Toyama Chemical (a subsidiary of Fujifilm), Favipiravir was approved in 2014 for the treatment of novel and re-emerging influenza viruses. Since then, its therapeutic profile has expanded, and it is now being evaluated for efficacy against various RNA viruses, including Ebola, Lassa fever, and SARS-CoV-2.

Chemical and Pharmacological Profile

  • Chemical Name: 6-fluoro-3-hydroxy-2-pyrazinecarboxamide

  • Molecular Formula: C5H4FN3O2

  • Drug Class: RNA-dependent RNA polymerase inhibitor (RdRp inhibitor)

  • Mechanism of Action: Favipiravir is a prodrug that is intracellularly converted into its active form, Favipiravir-RTP (ribofuranosyl-5'-triphosphate). This metabolite inhibits viral RNA-dependent RNA polymerase, thereby preventing viral replication. It selectively targets viral polymerases without significantly affecting human DNA or RNA polymerases.

Therapeutic Indications

Favipiravir has shown antiviral activity against a wide range of RNA viruses. Its current and potential indications include:

  • Influenza (seasonal, pandemic, avian, and novel strains)

  • Ebola virus disease

  • Lassa fever

  • Nipah virus infection

  • Zika virus infection

  • COVID-19 (off-label/emergency use in some countries)

Favipiravir and COVID-19

During the COVID-19 pandemic, Favipiravir was one of the repurposed drugs tested for effectiveness against SARS-CoV-2. Initial studies from countries like China, India, and Russia showed promise, with faster viral clearance and shorter recovery times in mild to moderate cases.

  • Mechanism in COVID-19: As an RdRp inhibitor, Favipiravir disrupts SARS-CoV-2 replication, potentially reducing viral load and transmission.

  • Clinical Trials: Multiple randomized controlled trials have been conducted, though with mixed outcomes. Some studies showed reduced time to clinical improvement, while others found no significant difference compared to standard care.

  • Regulatory Status: Approved for emergency or restricted use in countries like India, Russia, and UAE for mild to moderate COVID-19 cases. Not approved in the U.S. or Europe for this indication.

Dosing and Administration

  • Influenza (Japan-approved dosing):

    • Loading dose: 1600 mg twice daily on Day 1

    • Maintenance dose: 600 mg twice daily from Day 2 to Day 5

  • COVID-19 (used in clinical trials):

    • Loading dose: 1800 mg twice daily on Day 1

    • Maintenance dose: 800 mg twice daily for 7–14 days

  • Formulation: Oral tablets, typically 200 mg

Pharmacokinetics

  • Absorption: Rapidly absorbed after oral administration

  • Metabolism: Primarily metabolized by aldehyde oxidase and partly by xanthine oxidase

  • Half-life: ~2–5 hours (may vary with hepatic function)

  • Excretion: Primarily via urine as hydroxylated metabolites

Safety and Adverse Effects

While generally well-tolerated, Favipiravir has several known side effects:

  • Common Adverse Effects:

    • Hyperuricemia (increased uric acid levels)

    • Diarrhea

    • Elevated liver enzymes

    • Nausea

    • Dizziness

  • Serious Concerns:

    • Teratogenicity: Animal studies have shown embryotoxicity and teratogenic effects. Contraindicated in pregnancy.

    • Reproductive Toxicity: Should be avoided in women who are pregnant or may become pregnant. Men are advised to use contraception during and after treatment.

Contraindications and Precautions

  • Contraindicated in:

    • Pregnant women

    • Lactating women

    • Individuals with severe renal or hepatic impairment

  • Precautions:

    • Monitor uric acid levels and liver function tests

    • Use with caution in patients with gout

Drug Interactions

  • With xanthine oxidase inhibitors (e.g., allopurinol): May alter Favipiravir metabolism

  • With antacids containing aluminum or magnesium: May reduce absorption

  • Other antivirals: Combined antiviral therapies are under investigation, but data are limited

Resistance Potential

Favipiravir has a high barrier to resistance due to its broad-spectrum activity and the essential nature of the RdRp enzyme in viral replication. However, prolonged use and subtherapeutic dosing can contribute to resistance.

Ongoing Research and Clinical Trials

Favipiravir continues to be evaluated in multiple settings:

  • Influenza pandemic preparedness

  • Hemorrhagic fevers (Ebola, Lassa)

  • Combination therapies with other antivirals (e.g., Remdesivir, Molnupiravir)

  • Prophylactic use in exposed populations

Regulatory Status Worldwide

  • Japan: Approved for influenza under the name Avigan

  • India: Emergency use approval for COVID-19 (marketed as Fabiflu)

  • Russia, UAE, Saudi Arabia: Approved or authorized for limited COVID-19 treatment

  • USA/Europe: Not yet approved by the FDA or EMA

Market and Commercialization

Favipiravir has been produced and marketed under various brand names:

  • Avigan (Japan)

  • Fabiflu (India)

  • Areplivir (Russia)

  • Covifor (Bangladesh)

Advantages of Favipiravir

  • Oral formulation: Suitable for outpatient treatment

  • Broad-spectrum activity: Effective against various RNA viruses

  • Early symptom control: Especially beneficial when administered early in the course of disease

Limitations and Criticisms

  • Limited robust data for COVID-19: Conflicting trial outcomes

  • Not effective in severe cases: Most benefit seen in mild/moderate infections

  • Concerns over safety in pregnancy

  • Cost and accessibility in some regions

Patient Counseling Points

  • Take medication as prescribed and do not self-medicate

  • Women of childbearing age should use effective contraception

  • Report any side effects such as rash, jaundice, or severe gastrointestinal symptoms

  • Avoid use during pregnancy or breastfeeding

Future Prospects

With its broad-spectrum antiviral activity and potential applications beyond influenza, Favipiravir remains a significant candidate for future outbreak preparedness. Ongoing research into novel formulations, combination therapies, and expanded indications could further solidify its place in antiviral pharmacotherapy.

Conclusion

Favipiravir represents a promising antiviral agent with a unique mechanism of action and a growing range of therapeutic applications. While initially designed for influenza, its potential has expanded to include a variety of RNA viruses, including emerging global threats. Despite some limitations in evidence and safety concerns in special populations, Favipiravir offers hope in the ongoing battle against viral epidemics and pandemics. As clinical data accumulate and global experience with the drug grows, its role in the antiviral arsenal is likely to evolve further.